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Abstract
This short technical paper advocates a bootstrapping algorithm from which we can form a 
statistically reliable opinion based on limited clinically observed data, regarding whether
an osteo-hyperplasia could actually be a case of Ewing’s osteosarcoma. The basic 
premise underlying our methodology is that a primary bone tumour, if it is indeed 
Ewing’s osteosarcoma, cannot increase in volume beyond some critical limit without 
showing metastasis. We propose a statistical method to extrapolate such critical limit to 
primary tumour volume. Our model does not involve any physiological variables but 
rather is entirely based on time series observations of increase in primary tumour volume 
from the point of initial detection to the actual detection of metastases. 
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2I. Introduction
To date, oncogenetic studies of EWS/FLI-11 induced malignant transformation have 
largely relied upon experimental manipulation of Ewing’s bone tumour cell lines and 
fibroblasts that have been induced to express the oncogene. It has been shown that the 
biology of Ewing’s tumour cells in vitro is dramatically different between cells grown as 
mono-layers and cells grown as anchorage-independent, multi-cellular spheroids (MCS).
The latter is more representative of primary Ewing’s tumour in vivo (Lawlor et. al, 2002). 
MCS are clusters of cancer cells, used in the laboratory to study the early stages of 
avascular tumour growth. Mature MCS possess a well-defined structure, comprising a 
central core of necrotic i.e. dead cells, surrounded by a layer of non-proliferating, 
quiescent cells, with proliferating cells restricted to the outer, nutrient-rich layer of the 
tumour. As such, they are often used to assess the efficacy of new anti-cancer drugs and 
treatment therapies. The majority of mathematical models focus on the growth of MCS or 
avascular tumour growth. Most recent works have focused on the evolution of MCS 
growing in response to a single, externally-supplied nutrient, such as oxygen or glucose, 
and usually two growth inhibitors. 
Mathematical models of MCS growth typically consist of an ordinary differential 
equation (ODE) coupled to one or more reaction-diffusion equations (RDEs). The ODE 
is derived from mass conservation and describes the evolution of the outer tumour 
boundary, whereas the RDEs describe the distribution within the tumour of vital nutrients 
3such as oxygen and glucose and growth inhibitors (Dorman and Deutsch, 2002). 
However studies of this type, no matter how mathematically refined, often fall short of 
direct clinical applicability because of rather rigorous restrictions imposed on the 
boundary conditions. Moreover, these models focus more on the structural evolution of a 
tumour that is already positively classified as cancerous rather than on the clinically 
pertinent question of whether an initially benign growth can at a subsequent stage
become invasive and show metastases (De Vita et. al., 2001).
What we therefore aim to devise in our present paper is a bootstrapping algorithm from 
which we can form an educated opinion based on clinically observed data, regarding 
whether a bone growth initially diagnosed as benign can subsequently prove to be 
malignant (i.e. specifically, a case of Ewing’s osteosarcoma) . The strength of our 
proposed algorithm lies mainly in its computational simplicity – our model does not 
involve any physiological variables but is entirely based on time series observations of 
progression in tumour volume from the first observation point till detection of metastases. 
II. Literature support
In a clinical study conducted by Hense et. al. (1999), restricted to patients with suspected 
Ewing’s sarcoma, tumour volumes of more than 100 ml and the presence of primary
metastases were identified as determinants of poor prognosis in patients with such 
tumours. Diagnoses of primary tumours were ascertained exclusively by biopsies. The 
diagnosis of primary metastases was based on thoracic computed tomography or on 
4whole body bone scans. It was observed that of 559 of the patients (approx. 68% in a 
total sample size of 821) had a volume above 100 ml with smaller tumours being more 
common in childhood than in late adolescence and early adulthood. Extensive volumes 
were observed in almost 90% of the tumours located in femur and pelvis while they were 
less common in other sites (p < 0.001). On average, 26% of all patients were detected 
with clinically apparent primary metastases. 
The detection rate of metastases was markedly higher in patients diagnosed after 1991 (p
< 0.001). Primary metastases were also significantly more common for tumours 
originating in the pelvis and for other tumours in the Ewing’s family of tumours (EFT); 
mainly the peripheral neuro-ectodermal tumours (PNET); (p < 0.01). Tumours greater 
than 100 ml were positively associated with metastatic disease (p < 0.001). Multivariate 
analyses, which included simultaneously all univariate predictors in a logistic regression 
model, indicated the observed associations were mostly unconfounded.
Further it has been found that the metastatic potential of human tumours is encoded in the 
bulk of a primary tumour, thus challenging the notion that metastases arise from sparse
cells within a primary tumour that have the ability to metastasize (Sridhar Ramaswamy 
et. al., 2003). These studies lend credence to our fundamental premise about a critical 
primary tumour volume being used as a classification factor to distinguish between 
benign and potentially malignant bone growth.
5III. Statistical modelling methodology
Assuming that the temporal drift process governing the progression in size of a primary 
Ewing tumour of the bone to be linear (the computationally simplest process), we suggest 
a straightforward computational technique to generate a large family of possible tumour
propagation paths based on clinically observed growth patterns under laboratory 
conditions. In case the governing process is decidedly non-linear, then our proposed 
scheme would not be applicable and in such a case one will have to rely on a completely
non-parametric classification technique like e.g. an Artificial Neural Network (ANN). 
Our proposed approach is a bootstrapping one, whereby a linear autoregression model is 
fitted through the origin to the observation data in the first stage. If one or more beta 
coefficients are found to be significant at least at a 95% level for the fitted model then, in 
the second stage, the autoregression equation is formulated and solved as a linear 
difference equation to extract the governing equation. 
In the final stage, the governing equation obtained as above is plotted, for different values 
of the constant coefficients, as a family of possible temporal progression curves 
generated to explain the propagation property of that particular strain of tumour. The 
critical volume of the primary growth can thereafter be visually extrapolated from the 
observed cluster of points where the generated family of primary tumour progression
curves show a definite uptrend vis-a-vis the actual progression curve. 
6If no beta coefficient is found to be significant in the first stage, a non-linear temporal 
progression process is strongly suspected and the algorithm terminates without 
proceeding onto the subsequent stages, thereby implicitly recommending the problem to a 
non-parametric classification model.
The mathematical structure of our proposed model may be given as follows:
Progression in primary Ewing tumour size over time expressed as an n-step general 
autoregressive process through the origin:
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Formulated as a linear, difference equation we can write:
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Taking St common and applying the negative shift operator throughout, we get:
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Now applying the positive shift operator throughout we get:
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The characteristic equation of the above form is then obtained as follows:
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Here r is the root of the characteristic equation. After solving for r, the governing 
equation can be derived in accordance with the well-known analytical solution techniques 
for ordinary linear difference equations (Kelly and Peterson, 2000). 
IV. Simulated clinical study
We set up a simulated clinical study applying our modelling methodology with the 
following hypothetical primary Ewing tumour progression data adapted from the clinical 
study of Hense et. al. (1999) as given in Table I below:
8Table I
Observation (t) Primary Ewing tumour volume (in ml.)
(At point of first detection)
1 5
2 7
3 9
4 19
5 39
6 91
7 
(At the point of detection of metastasis)
102
Figure I
The temporal progression path of the primary growth from the point of first detection to 
the onset of metastasis is plotted above in Figure I.
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9We have fitted an AR (2) model to the primary tumour growth data as follows:
             E (St) = -1.01081081St-1 + 5.32365561St-2                                                        (VI)
The R2 of the fitted model is approximately 0.8311 and the F-statistic is 9.83832 with an 
associated p-value of approximately 0.04812. Therefore the fitted model definitely has an
overall predictive utility at the 5% level of significance. 
The residuals of the above AR (2) fitted model are given in Table II as follows:
Table II
Observation Predicted St Residuals
1 -5.05405405 12.05405405
2 19.5426024 -10.5426024
3 28.168292 -9.168292003
4 28.7074951 10.29250488
5 61.7278351 29.27216495
6 115.638785 -13.63878518
The average of the residuals comes to 3.044841. Therefore the linear difference equation 
to be solved in this case is as follows:
         Xt = -1.01081081Xt-1 + 5.32365561Xt-2 + 3.044841                                          (VII)
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Applying usual solution techniques, the general solution to equation (VII) is obtained as 
follows:
         Xt = c1 (2.43124756)
 t + c2 (-3.44205837)
 t                                                     (VIII)
Here c1 and c2 are the constant coefficients which may now be suitably varied to generate 
a family of possible primary tumour progression curves as in Figure II below:
Figure II
In the above plot, we have varied c2 in the range 0.01 to 0.10 and imposed the condition 
c1 = 1 – c2. The other obvious condition is that choice of c1 and c2 would be such as to 
rule out any absurd case of negative volume. Of course the choice of the governing 
equation parameters would also depend on specific clinical considerations (King, 2000).
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V. Conclusion
From Figure II, it becomes visually apparent that continuing increase in the observed size 
of the primary growth beyond approximately 52 ml. in volume would be potentially 
malignant as this would imply that the tumour would possibly keep exhibiting 
uncontrolled progression till it shows metastasis. This could also be obtained 
arithmetically as the average volume for t = 5.  Therefore the critical volume could be 
fixed around 52 ml. as per the computational results obtained in our illustrative example.  
Though our computational study is intended to be purely illustrative as we have worked 
with hypothetical figures and hence cannot yield any clinical conclusion, we believe we 
have hereby aptly demonstrated the essential algorithm of our statistical approach and 
justified its practical usability under laboratory settings.  We have used a difference 
equation model rather than a differential equation one because under practical laboratory 
settings, observations cannot be made continuously but only at discrete time intervals.
There is immediate scope of taking our line of research further forward by actually 
implementing an autoregressive process to model in vitro growth of MCS with real data.
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